Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06872333 · ClinicalTrials.gov registry record · Phase 2
Allo HSCT for High Risk Hemoglobinopathies
A Phase 2 study of Sickle Cell Disease and Hemoglobinopathies, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT06872333 is a Phase 2 study of Sickle Cell Disease and Hemoglobinopathies that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 62 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06872333, a Phase 2 study of Sickle Cell Disease and Hemoglobinopathies, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Alemtuzumab
- DRUG Thymoglobulin
- RADIATION Total Body Irradiation
- BIOLOGICAL Cell Infusion
Study Locations (1)
Minnesota
- Masonic Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2032-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06872333
The ClinicalTrials.gov registry entry for NCT06872333 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (79% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT06872333 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06872333 about?
NCT06872333 is a clinical study titled "Allo HSCT for High Risk Hemoglobinopathies". A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
What is the current status of trial NCT06872333?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2024-11-19. Estimated completion is 2032-06-01.
What conditions does trial NCT06872333 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Hemoglobinopathies, Graft Failure.
What interventions are being tested in trial NCT06872333?
The interventions under investigation include: Fludarabine (DRUG), Alemtuzumab (DRUG), Thymoglobulin (DRUG), Total Body Irradiation (RADIATION), Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT06872333?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06872333 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.